MRNA cancer vaccines enter human trials for multiple solid tumors
NCT ID NCT06880549
First seen Feb 05, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This early-stage trial tests two experimental mRNA therapies, mRNA-4106 and mRNA-4200, in 42 people with advanced solid tumors like melanoma, lung, liver, and ovarian cancers. The study aims to check safety and find the right dose, either alone or combined with the immunotherapy pembrolizumab. It is too early to know if these treatments will work, but they represent a new approach using mRNA to help the immune system fight cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
START San Antonio
San Antonio, Texas, 78229, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA-4106, mRNA-4200, and pembrolizumab
What this could lead to
If successful, this could point toward a new mRNA-based treatment option for several advanced cancers, potentially shrinking tumors or slowing their growth.
What could go wrong
This is a very early Phase 1 trial with only 42 participants, focused on safety and dosing. It is too soon to know if these mRNA therapies will work, and they may cause side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.